Recent advances in therapeutic strategies for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yun, Zhang, Huajun, Merkher, Yulia, Chen, Lin, Liu, Na, Leonov, Sergey, Chen, Yongheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422136/
https://www.ncbi.nlm.nih.gov/pubmed/36038913
http://dx.doi.org/10.1186/s13045-022-01341-0
_version_ 1784777748057686016
author Li, Yun
Zhang, Huajun
Merkher, Yulia
Chen, Lin
Liu, Na
Leonov, Sergey
Chen, Yongheng
author_facet Li, Yun
Zhang, Huajun
Merkher, Yulia
Chen, Lin
Liu, Na
Leonov, Sergey
Chen, Yongheng
author_sort Li, Yun
collection PubMed
description Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, represent promising treatment options against TNBC. In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review, we summarize recent key advances in therapeutic strategies based on molecular subtypes in TNBC.
format Online
Article
Text
id pubmed-9422136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94221362022-08-30 Recent advances in therapeutic strategies for triple-negative breast cancer Li, Yun Zhang, Huajun Merkher, Yulia Chen, Lin Liu, Na Leonov, Sergey Chen, Yongheng J Hematol Oncol Review Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, represent promising treatment options against TNBC. In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review, we summarize recent key advances in therapeutic strategies based on molecular subtypes in TNBC. BioMed Central 2022-08-29 /pmc/articles/PMC9422136/ /pubmed/36038913 http://dx.doi.org/10.1186/s13045-022-01341-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Li, Yun
Zhang, Huajun
Merkher, Yulia
Chen, Lin
Liu, Na
Leonov, Sergey
Chen, Yongheng
Recent advances in therapeutic strategies for triple-negative breast cancer
title Recent advances in therapeutic strategies for triple-negative breast cancer
title_full Recent advances in therapeutic strategies for triple-negative breast cancer
title_fullStr Recent advances in therapeutic strategies for triple-negative breast cancer
title_full_unstemmed Recent advances in therapeutic strategies for triple-negative breast cancer
title_short Recent advances in therapeutic strategies for triple-negative breast cancer
title_sort recent advances in therapeutic strategies for triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422136/
https://www.ncbi.nlm.nih.gov/pubmed/36038913
http://dx.doi.org/10.1186/s13045-022-01341-0
work_keys_str_mv AT liyun recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer
AT zhanghuajun recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer
AT merkheryulia recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer
AT chenlin recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer
AT liuna recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer
AT leonovsergey recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer
AT chenyongheng recentadvancesintherapeuticstrategiesfortriplenegativebreastcancer

Ejemplares similares